Related Experiment Video
Updated: Jul 17, 2025
07:53
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
4.3K
Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple
Travis S Johnson1,2,3,4, Parvathi Sudha5, Enze Liu5
1Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.
Research Square
|August 30, 2023
Summary
Researchers identified a specific subtype of plasma cells, termed relapsed/refractory plasma cells (RRPCs), associated with multiple myeloma progression. These RRPCs exhibit high PHF19 expression and are linked to treatment resistance and poor outcomes.
Area of Science:
- Hematology
- Oncology
- Genomics
Background:
- Multiple Myeloma (MM) is an incurable plasma cell cancer with limited treatment options.
- Therapeutic resistance to immunomodulatory drugs (iMiDs) and proteasome inhibitors (PIs) is a major challenge in MM management.
- Previous studies identified genetic and transcriptional markers, including PHF19, associated with high-risk MM.
Conclusions:
- PHF19 plays a significant role in the biology of RRPCs and MM progression.
- The identified RRPC subtype represents a critical target for understanding and overcoming therapeutic resistance in MM.
- Single-cell multiomics provides powerful insights into the heterogeneity and evolution of multiple myeloma.
